

THE STOCK EXCHANGE OF HONG KONG LIMITED*(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)***REGULATORY FORMS****FORMS RELATING TO LISTING****FORM G****GEM****COMPANY INFORMATION SHEET**

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: China Biotech Services Holdings Limited

Stock code (ordinary shares): 8037

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on GEM of The Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the Exchange’s website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 3 August 2026.

A. General

Place of incorporation: Incorporated in the Cayman Islands and continued in Bermuda

Date of initial listing on GEM: 17 June 2004

Name of Sponsor(s): N/A

Names of directors:
(please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)

Executive Directors
Mr. LIU Xiaolin (Chairman)
Dr. HUANG Song
Dr. YIN Ye

Independent Non-executive Directors
Mr. YAN Guoxiang
Dr. GUO Yuantao
Dr. ZHANG Xiao

THE STOCK EXCHANGE OF HONG KONG LIMITED*(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)*

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name	Nature of interest	No. of ordinary shares of the Company (the "Shares") held	Approximate percentage of total issued share capital of the Company
---	------	--------------------	---	---

Genius Lead Limited ("Genius Lead")	Beneficial owner	529,500,546	54.27%
Genius Earn Limited ("Genius Earn") (Note 1)	Interest of a controlled corporation	529,500,546	54.27%
Mr. LIU Xiaolin ("Mr. Liu") (Note 2)	Interest of a controlled corporation and beneficial owner	534,192,546	54.75%

Notes:

1. Genius Lead is wholly-owned by Genius Earn. As such, Genius Earn is deemed to be interested in the shares of the Company which Genius Lead is interested in.
2. Mr. Liu is interested in 4,692,000 Shares as beneficial owner. Additionally, Genius Earn is wholly-owned by Mr. Liu. Mr. Liu is therefore deemed to be interested in the shares of the Company which Genius Earn is interested in.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:

N/A

Financial year end date:

31 December

Registered address:

Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda

Head office and principal place of business:

Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong

Web-site address (if applicable):

www.cbshhk.com

THE STOCK EXCHANGE OF HONG KONG LIMITED*(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)*

Share registrar:

Principal Share Registrar and Transfer Office

Conyers Corporate Services (Bermuda) Limited
 Richmond House
 12 Par-la-Ville Road
 Hamilton HM 08
 Bermuda

Hong Kong Branch Share Registrar and Transfer Office

Union Registrars Limited
 Suites 3301-04, 33/F.
 Two Chinachem Exchange Square
 338 King's Road
 North Point
 Hong Kong

Auditors:

RSM Hong Kong
 29th Floor, Lee Garden Two
 28 Yun Ping Road, Causeway Bay, Hong Kong

B. Business activities*(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)*

The principal activity of the Company is investment holding. The principal activities of its subsidiaries are (i) provision of medical laboratory testing services and health check services in Hong Kong; (ii) provision of tumor immune cell therapy and health management services in the People's Republic of China (the "PRC"); (iii) sale and distribution of health related and pharmaceutical products in the PRC and Hong Kong; (iv) provision of boron neutron capture therapy services in the PRC and (v) provision of insurance brokerage services in Hong Kong.

C. Ordinary sharesNumber of ordinary shares in issue: 975,731,150Par value of ordinary shares in issue: HK\$0.10Board lot size (in number of shares): 5,000 sharesName of other stock exchange(s) on which ordinary shares are also listed: N/A**D. Warrants**Stock code: N/ABoard lot size: N/AExpiry date: N/AExercise price: N/AConversion ratio: N/A

*(Not applicable if the warrant is
 denominated in dollar value of
 conversion right)*

No. of warrants outstanding: N/A

THE STOCK EXCHANGE OF HONG KONG LIMITED*(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)*

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

Convertible Bonds

On 27 December 2024, convertible bonds in the aggregate principal amount of US\$6,000,000 (the "2024 Convertible Bonds") were issued by the Company to Guoyuan Securities Investment (Hong Kong) Limited pursuant to the subscription agreement dated 17 December 2024 entered into between the Company and Guoyuan Securities Investment (Hong Kong) Limited. Based on the initial conversion price of HK\$1.20 per conversion share at the exchange rate of HK\$7.85 to US\$1.00, a maximum number of 39,250,000 conversion shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the Convertible Bonds in full. As a result of completion of the issue of the 2026 Convertible Bonds (as defined below) on 20 February 2026, the conversion price of the 2024 Convertible Bonds is adjusted from HK\$1.20 per share to HK\$1.11 per share and the maximum number of shares to be allotted and issued by the Company upon conversion of the 2024 Convertible Bonds in full is 42,432,432 shares. The maturity date of the 2024 Convertible Bonds is 27 December 2026.

On 20 February 2026, convertible bonds in the aggregate principal amount of US\$35,000,000 (the "2026 Convertible Bonds") were issued by the Company to Wealth Strategy Holding Limited pursuant to the conditional subscription agreement dated 29 December 2025 entered into between the Company and Wealth Strategy Holding Limited. Based on the initial conversion price of HK\$0.66 per conversion share at the exchange rate of HK\$7.78 to US\$1.00, a maximum number of 412,575,757 conversion shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the 2026 Convertible Bonds in full. The maturity date of the 2026 Convertible Bonds is 20 February 2030.

As at the date hereof, US\$6,000,000 of the principal amount of the 2024 Convertible Bonds and US\$35,000,000 of the principal amount of the 2026 Convertible Bonds remain outstanding.

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

THE STOCK EXCHANGE OF HONG KONG LIMITED*(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)***Responsibility statement**

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by: LIU Xiaolin
(Name)

Title: Director
(Director, secretary or other duly authorised officer)

NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the Exchange’s website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.